A Phase II Study of TARCEVA (erlotinib) in Combination with Chemoradiation in Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase II Study of TARCEVA (erlotinib) in Combination with Chemoradiation in Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
    • 09 Sep 2015 Interim results (n= 59) presented at the 16th World Conference on Lung Cancer
    • 01 Jun 2015 Interim results (n=46) published in the International Journal of Radiation Oncology, Biology, Physics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top